790 related articles for article (PubMed ID: 28077654)
1. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
[TBL] [Abstract][Full Text] [Related]
2. Soluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes.
Loughney JW; Rustandi RR; Wang D; Troutman MC; Dick LW; Li G; Liu Z; Li F; Freed DC; Price CE; Hoang VM; Culp TD; DePhillips PA; Fu TM; Ha S
J Biol Chem; 2015 Jun; 290(26):15985-95. PubMed ID: 25947373
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.
Chiuppesi F; Wussow F; Johnson E; Bian C; Zhuo M; Rajakumar A; Barry PA; Britt WJ; Chakraborty R; Diamond DJ
J Virol; 2015 Dec; 89(23):11884-98. PubMed ID: 26378171
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibodies to Different Components of the Human Cytomegalovirus (HCMV) Pentamer gH/gL/pUL128L and Trimer gH/gL/gO as well as Antibodies Elicited during Primary HCMV Infection Prevent Epithelial Cell Syncytium Formation.
Gerna G; Percivalle E; Perez L; Lanzavecchia A; Lilleri D
J Virol; 2016 Jul; 90(14):6216-6223. PubMed ID: 27122579
[TBL] [Abstract][Full Text] [Related]
5. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.
Freed DC; Tang Q; Tang A; Li F; He X; Huang Z; Meng W; Xia L; Finnefrock AC; Durr E; Espeseth AS; Casimiro DR; Zhang N; Shiver JW; Wang D; An Z; Fu TM
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):E4997-5005. PubMed ID: 24297878
[TBL] [Abstract][Full Text] [Related]
6. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
[TBL] [Abstract][Full Text] [Related]
7. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.
Fu TM; Wang D; Freed DC; Tang A; Li F; He X; Cole S; Dubey S; Finnefrock AC; ter Meulen J; Shiver JW; Casimiro DR
Vaccine; 2012 Dec; 30(52):7469-74. PubMed ID: 23107592
[TBL] [Abstract][Full Text] [Related]
8. Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo.
Lilleri D; Kabanova A; Lanzavecchia A; Gerna G
J Clin Immunol; 2012 Dec; 32(6):1324-31. PubMed ID: 22836657
[TBL] [Abstract][Full Text] [Related]
9. Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response.
Lehmann C; Falk JJ; Büscher N; Penner I; Zimmermann C; Gogesch P; Sinzger C; Plachter B
J Virol; 2019 Sep; 93(17):. PubMed ID: 31189713
[TBL] [Abstract][Full Text] [Related]
10. A Novel Strain-Specific Neutralizing Epitope on Glycoprotein H of Human Cytomegalovirus.
Thomas M; Kropff B; Schneider A; Winkler TH; Görzer I; Sticht H; Britt WJ; Mach M; Reuter N
J Virol; 2021 Aug; 95(18):e0065721. PubMed ID: 34160252
[TBL] [Abstract][Full Text] [Related]
11. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.
Wen Y; Monroe J; Linton C; Archer J; Beard CW; Barnett SW; Palladino G; Mason PW; Carfi A; Lilja AE
Vaccine; 2014 Jun; 32(30):3796-804. PubMed ID: 24837507
[TBL] [Abstract][Full Text] [Related]
12. Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections.
Genini E; Percivalle E; Sarasini A; Revello MG; Baldanti F; Gerna G
J Clin Virol; 2011 Oct; 52(2):113-8. PubMed ID: 21820353
[TBL] [Abstract][Full Text] [Related]
13. Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.
Schneider-Ohrum K; Cayatte C; Liu Y; Wang Z; Irrinki A; Cataniag F; Nguyen N; Lambert S; Liu H; Aslam S; Duke G; McCarthy MP; McCormick L
J Virol; 2016 Nov; 90(22):10133-10144. PubMed ID: 27581989
[TBL] [Abstract][Full Text] [Related]
14. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex.
Wussow F; Chiuppesi F; Martinez J; Campo J; Johnson E; Flechsig C; Newell M; Tran E; Ortiz J; La Rosa C; Herrmann A; Longmate J; Chakraborty R; Barry PA; Diamond DJ
PLoS Pathog; 2014 Nov; 10(11):e1004524. PubMed ID: 25412505
[TBL] [Abstract][Full Text] [Related]
15. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.
Wussow F; Yue Y; Martinez J; Deere JD; Longmate J; Herrmann A; Barry PA; Diamond DJ
J Virol; 2013 Feb; 87(3):1322-32. PubMed ID: 23152525
[TBL] [Abstract][Full Text] [Related]
16. A Fully Protective Congenital CMV Vaccine Requires Neutralizing Antibodies to Viral Pentamer and gB Glycoprotein Complexes but a pp65 T-Cell Response Is Not Necessary.
Choi KY; McGregor A
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452332
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model.
Valencia S; Gill RB; Dowdell KC; Wang Y; Hornung R; Bowman JJ; Lacayo JC; Cohen JI
Vaccine; 2019 Jan; 37(2):333-342. PubMed ID: 30522906
[TBL] [Abstract][Full Text] [Related]
18. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection.
Lilleri D; Kabanova A; Revello MG; Percivalle E; Sarasini A; Genini E; Sallusto F; Lanzavecchia A; Corti D; Gerna G
PLoS One; 2013; 8(3):e59863. PubMed ID: 23555812
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
Adler SP; Lewis N; Conlon A; Christiansen MP; Al-Ibrahim M; Rupp R; Fu TM; Bautista O; Tang H; Wang D; Fisher A; Culp T; Das R; Beck K; Tamms G; Musey L;
J Infect Dis; 2019 Jul; 220(3):411-419. PubMed ID: 31535143
[TBL] [Abstract][Full Text] [Related]
20. Neutralization Epitopes in Trimer and Pentamer Complexes Recognized by Potent Cytomegalovirus-Neutralizing Human Monoclonal Antibodies.
Ai Y; Wu C; Zhang M; Jaijyan DK; Liu T; Zan L; Li N; Yu W; Wang Y; Yuan X; Li C; Zheng W; Zhu H; Liao HX
Microbiol Spectr; 2022 Dec; 10(6):e0139322. PubMed ID: 36342276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
